2021-10-19T12:43:17-05:00 2020-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2020-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY % LINDA JENSEN CFO CONQ 5714831700 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2021-10-14 true LINDA JENSEN 999009999 Marc Berger P01871563 7038930600 3 2020 2022-09-23 18:48:47Z CONQUER CANCER & CONQUER CANCER FDN NANCY DALY MS MPH 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 91005382 false X WWW.CONQUER.ORG X 1999 VA CONQUERING CANCER WORLDWIDE BY FUNDING BREAKTHROUGH RESEARCH AND SHARING CUTTING-EDGE KNOWLEDGE. CONQUER CANCER'S VISION IS A WORLD FREE FROM THE FEAR OF CANCER. 18 17 0 152 472500 350485 27209762 34795083 522500 622500 2692338 -2363054 26046 -11891 30450646 33042638 15020244 14740700 0 0 0 0 222000 222000 5743010 9672350 10278908 24914594 25241608 5536052 7801030 89666380 107923414 7196521 9249329 82469859 98674085 X CONQUER CANCER , THE ASCO FOUNDATION, FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. IN 1964, SEVEN ONCOLOGISTS CREATED THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), NOW A GLOBAL NETWORK OF NEARLY 45,000 CANCER PROFESSIONALS. AS ASCO'S FOUNDATION, CONQUER CANCER HELPS TURN SCIENCE INTO A SIGH OF RELIEF FOR PATIENTS AROUNDS THE WORLD BY SUPPORTING GROUNDBREAKING RESEARCH AND EDUCATION ACROSS CANCER'S FULL CONTINUUM. false false 4926145 4467677 472500 PROFESSIONAL EDUCATION - CONQUER CANCER HELPS ONCOLOGY PROFESSIONALS WORLDWIDE STAY UP TO DATE ON THE LATEST DEVELOPMENTS AND DISCOVERIES IN CANCER KNOWLEDGE. CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S COMPREHENSIVE SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND PRINT AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2020 INCLUDE THE FOLLOWING: * THE VIRTUAL ASCO ANNUAL MEETING FEATURED NEARLY 200 EDUCATIONAL AND SCIENTIFIC SESSIONS. NEARLY 5,300 ABSTRACTS WERE PRESENTED OR PUBLISHED. THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY AND ATTRACTS MORE THAN 40,000 ATTENDEES WORLDWIDE. THE MEETING OFFERS HEALTHCARE PROFESSIONALS PROVIDING ONCOLOGY CARE AN IMPORTANT OPPORTUNITY TO COME TOGETHER TO EXPLORE THE LATEST ADVANCES IN SCIENCE; CONTEXTUALIZE RECENT DISCOVERIES AND OPTIMIZE TREATMENT AND RESEARCH STRATEGIES; FRAME AND DISCUSS MAJOR CONTROVERSIES IN THE FIELD; AND NETWORK WITH PEERS IN AN ENVIRONMENT CHARGED WITH THE EXCITEMENT OF A COMMON GOAL: PROGRESS TOWARD BETTER OUTCOMES FOR PATIENTS. * GASTROINTESTINAL CANCERS (GI) SYMPOSIUM - THE ANNUAL GI SYMPOSIUM IS THE PREMIERE MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY A COMMITTEE WITH REPRESENTATIVES FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE (AGA INSTITUTE), THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO), AND THE SOCIETY OF SURGICAL ONCOLOGY (SSO). * GENITOURINARY CANCERS (GU) SYMPOSIUM - THE ANNUAL GU SYMPOSIUM IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY COMMITTEES WITH REPRESENTATIVES FROM THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO), AND THE SOCIETY OF UROLOGIC ONCOLOGY (SUO). *QUALITY CARE SYMPOSIUM - THE ASCO QUALITY CARE SYMPOSIUM PROVIDES A FORUM TO SHARE THE LATEST STRATEGIES AND METHODS FOR QUANTIFICATION OF PATIENT EXPERIENCE, PROVIDER EFFICIENCY, CLINICAL OUTCOMES, AND QUALITY AND SAFETY IN THE CANCER CARE FIELD. THE SYMPOSIUM BRINGS TOGETHER LEADERS IN THE FIELD TO SHARE STRATEGIES AND METHODS FOR MEASURING AND IMPROVING THE QUALITY OF CANCER CARE AND DISSEMINATES INFORMATION ON THE IMPROVEMENT OF THE QUALITY OF PATIENT AND SURVIVOR CARE THROUGH IMPLEMENTATION SCIENCE AND METHODS FOR QUANTIFICATION OF PATIENT EXPERIENCES, PROVIDER EFFICIENCY, CLINICAL OUTCOMES, SAFETY, AND VALUE. *IMMUNO-ONCOLOGY SYMPOSIUM - THE ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM EXPLORES CLINICAL AND TRANSLATIONAL RESEARCH IN IMMUNO-ONCOLOGY AND IMPLICATIONS FOR PATIENT CARE. THE SYMPOSIUM FACILITATES IMPORTANT EDUCATIONAL AND SCIENTIFIC DIALOGUES ON CLINICAL DEVELOPMENTS ACROSS DISEASE SITES IN THE RAPIDLY ADVANCING FIELD OF IMMUNO-ONCOLOGY AND HELPS MEET THE WIDESPREAD NEED FOR EDUCATION IN RESPONSE TO A PARADIGM SHIFT IN CANCER TREATMENT THAT TARGETS THE IMMUNE SYSTEM RATHER THAN THE TUMOR. THE SYMPOSIUM IS DEVELOPED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) AND THE SOCIETY FOR THE IMMUNOTHERAPY OF CANCER (SITC). *EDUCATION SCHOLARS PROGRAM (ESP) - THE EDUCATION SCHOLARS PROGRAM IS A YEARLONG PROFESSIONAL DEVELOPMENT INITIATIVE, WHICH AIMS TO CREATE A COHORT OF ONCOLOGISTS WITH BOTH LEADERSHIP SKILLS AND EXPERTISE IN LEARNING SCIENCE AND EDUCATION DESIGN. THROUGH THIS PROGRAM, ESP PARTICIPANTS WILL BECOME EXPERIENCED IN USING THE LATEST LEARNING SCIENCE TO MORE EFFECTIVELY PRESENT GROUND-BREAKING CANCER DEVELOPMENTS TO THE ONCOLOGY COMMUNITY TO ADVANCE CANCER RESEARCH AND IMPROVE PATIENT CARE. PARTICIPANTS IN THE EDUCATION SCHOLARS PROGRAM WILL RECEIVE DIDACTIC AND HANDS-ON TRAINING BY LEARNING SCIENCE SCHOLARS ON HOW TO DESIGN EFFECTIVE EDUCATIONAL PROGRAMS FOR ADULT LEARNERS. HIGHLIGHTS OF PRINT AND ELECTRONIC PROFESSIONAL EDUCATION MATERIALS SUPPORTED BY CONQUER CANCER AND AVAILABLE TO THE PUBLIC IN 2020 INCLUDE THE FOLLOWING: *MEETING LIBRARY- ASCO'S MEETING LIBRARY IS A ONE-STOP LOCATION TO ACCESS ABSTRACTS, VIDEOS, SLIDES, AND POSTERS PRESENTED AT ASCO'S MEETINGS, BOTH DOMESTIC AND INTERNATIONAL. MEETING LIBRARY FOCUSES ON SEARCH AND CONTENT FILTERS AS ITS PRIMARY MEANS TO FIND AND ACCESS VARIOUS FORMS OF MEDIA, ALL OF WHICH ARE GROUPED TOGETHER ON A SINGLE PAGE. OVER THE COURSE OF THE UPCOMING YEAR, MEETING LIBRARY WILL CONTINUE TO BE ENHANCED INCLUDING EFFORTS TO PERSONALIZE AND DISPLAY CONTENT IN A MORE USER-FRIENDLY WAY. SEVERAL FEATURES THAT HAVE ALREADY BEEN ADDED TO THE MEETING LIBRARY INCLUDE TRANSCRIPTION AND CLOSED CAPTIONING OF VIDEO, THE ABILITY TO SEARCH WITHIN PRESENTATION VIDEOS, AND THE ABILITY TO CREATE A COLLECTION WITH FAVORITE CONTENT TO MAKE FOR A MORE USER-FRIENDLY EXPERIENCE. *ASCO CLINICAL GUIDELINES MOBILE APPLICATION - ASCO DEVELOPS AND PUBLISHES CLINICAL PRACTICE GUIDELINES TO SERVE AS A GUIDE FOR DOCTORS AND OUTLINE APPROPRIATE METHODS OF TREATMENT AND CARE. THE GUIDELINES CAN ALSO ADDRESS SPECIFIC DISEASE-ORIENTED CLINICAL SITUATIONS, AS WELL AS USE OF APPROVED MEDICAL PRODUCTS, PROCEDURES, AND TESTS. THE ASCO CLINICAL PRACTICE GUIDELINES MOBILE APPLICATION IS DESIGNED TO MAKE ASCO GUIDELINES MORE USER-FRIENDLY BY PROVIDING INTERACTIVE TOOLS AND GUIDELINES FOR USE AT THE BEDSIDE AND/OR IN CLINIC BY MEMBERS OF THE ONCOLOGY CARE TEAM, WITH THE ULTIMATE RESULT OF IMPROVING PATIENT CARE BASED ON ESTABLISHED SCIENCE AND THE LATEST RESEARCH. NEW DEVELOPMENTS IN THE APPLICATION INCLUDE THE ABILITY TO PROVIDE CREDIT FOR UP TO 2 MERIT-BASED INCENTIVE PAYMENT SYSTEM IMPROVEMENT ACTIVITIES AS WELL AS THE INCLUSION OF 27 ASCO CLINICAL PRACTICE GUIDELINES IN MULTIPLE CANCER TYPES. *MERIT AWARDS- $166,000 PROVIDED FOR ONE-HUNDRED SIXTY-FOUR (164)MERIT AWARDS WHICH PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AND INTERACT WITH OTHER CLINICAL CANCER INVESTIGATORS AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. *MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR)- $93,500 PROVIDED FOR ELEVEN (11) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER AND ALLOWS THEM TO GAIN KNOWLEDGE AND EXPERIENCE IN THE AREAS OF CLINICAL CANCER CARE AND RESEARCH. A MENTORING COMPONENT IS INCLUDED IN THE MSR WHEREBY AWARD RECIPIENTS ARE PAIRED WITH A CLINICAL ONCOLOGIST WHO PROVIDES ACADEMIC AND CAREER GUIDANCE, BOTH DURING AND FOLLOWING THE ROTATION EXPERIENCE. *RESIDENT TRAVEL AWARD FOR UNDERREPRESENTED POPULATIONS - $10,500 PROVIDED FOR SEVEN (7) RESIDENT TRAVEL AWARDS (RTA). THE RTA PROVIDES FINANCIAL SUPPORT FOR RESIDENTS FROM UNDERREPRESENTED POPULATIONS TO ATTEND THE virtual ASCO ANNUAL MEETING. ATTENDING THE VIRTUAL ASCO ANNUAL MEETING GIVES PHYSICIAN RESIDENTS INTERESTED IN A CAREER IN ONCOLOGY THE OPPORTUNITY TO MEET ONCOLOGISTS AND TO LEARN MORE ABOUT CAREER OPTIONS IN THE FIELD. 13473905 10179024 150000 RESEARCH - THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER HAS A DEMONSTRATED TRACK RECORD IN SUPPORTING THE EARLY CAREER DEVELOPMENT OF ONCOLOGY RESEARCHERS, INCLUDING IDENTIFYING AND NURTURING THOSE WHO HAVE BECOME NOTABLE LEADERS AND INNOVATORS IN THE FIELD. PAST GRANT RECIPIENTS HAVE BECOME HEADS OF LARGE CANCER INSTITUTIONS AND PRESIDENTS OF MAJOR ONCOLOGY SOCIETIES, AS WELL AS GUIDED THE NATIONAL ONCOLOGY CONVERSATION THROUGH SERVICE ON BOARDS AND COMMITTEES. ADDITIONALLY, PAST RECIPIENTS HAVE ALSO INVESTED IN THE NEXT GENERATION OF YOUNG INVESTIGATORS BY SERVING AS MENTORS TO NEWLY CHOSEN CONQUER CANCER GRANTEES. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. EACH YEAR CONQUER CANCER FUNDS AND AWARDS MULTIPLE RESEARCH GRANTS DESIGNED TO HELP ATTRACT AND RETAIN THE BEST SCIENTIFIC MINDS IN CANCER RESEARCH AND TO SUPPORT THEIR EFFORTS. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $135 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,200 RECIPIENTS IN 77 COUNTRIES. HIGHLIGHTS OF 2020 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: RESEARCH PROFESSORSHIP (RP) - $500,000 PROVIDED ONE (1) FIVE-YEAR AWARD TO SUPPORT A FULL PROFESSOR WHO HAS MADE SIGNIFICANT CONTRIBUTIONS TO CANCER RESEARCH AND ARE DEDICATED TO MENTORING THE NEXT GENERATION OF RESEARCHERS. ADVANCED CLINICAL RESEARCH AWARD (ACRA) - $450,000 PROVIDED ONE (1) THREE-YEAR AWARD TO SUPPORT A PHYSICIAN-SCIENTIST COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH IN BREAST CANCER. THIS RESEARCH MUST HAVE A PATIENT-ORIENTED FOCUS, INCLUDING A CLINICAL RESEARCH STUDY AND/OR TRANSLATIONAL RESEARCH INVOLVING HUMAN SUBJECTS. CAREER DEVELOPMENT AWARD (CDA) - $3,200,000 PROVIDED SIXTEEN (16) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. YOUNG INVESTIGATOR AWARD (YIA) - $3,950,000 PROVIDED SEVENTY-NINE (79) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD - $239,494 PROVIDED FIVE (5) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS CONDUCTING RESEARCH IN LOW RESOURCE SETTINGS ON SCIENTIFIC QUESTIONS SPECIFIC TO THOSE SETTINGS, WITH THE POTENTIAL TO OFFER "REVERSE INNOVATION" INSIGHTS TO INFLUENCE ONCOLOGY PRACTICE IN A WIDE RANGE OF RESOURCE SETTINGS, BY INVESTIGATORS IN HIGH RESOURCE SETTINGS ON ISSUES IN RESOURCE-LIMITED SETTINGS, OR COLLABORATIVE RESEARCH BETWEEN INVESTIGATORS IN BOTH HIGH AND LOW RESOURCE SETTINGS ON QUESTIONS OF SHARED CONCERN. THE GOAL FOR THE GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD IS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY, AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS. LONG-TERM INTERNATIONAL FELLOWSHIP (LIFE) - $115,000 PROVIDED ONE (1) ONE-YEAR FELLOWSHIP TO AN EARLY-CAREER ONCOLOGIST IN A LOW- TO MIDDLE-INCOME COUNTRY (LMCS) THE SUPPORT AND RESOURCES NEEDED TO ADVANCE THEIR TRAINING BY DEEPENING THEIR RELATIONSHIP WITH A MENTOR IN THE UNITED STATES, CANADA, OR THE EUROPEAN UNION (EU). DURING THEIR ONE-YEAR FELLOWSHIP, THE RECIPIENT RECEIVES VALUABLE TRAINING AND EXPERIENCE, WHICH THEY WILL USE TO AFFECT CHANGE IN CANCER CARE IN THEIR HOME COUNTRY. FELLOWSHIPS ARE A COMBINATION OF CLINICAL TRAINING AND CLINICAL AND LABORATORY RESEARCH IN ACCORDANCE WITH INSTITUTIONAL RULES AND REGULATIONS. RECIPIENTS ARE REQUIRED TO RETURN TO THEIR HOME INSTITUTIONS AFTER THE FELLOWSHIP PERIOD TO DISSEMINATE THE KNOWLEDGE THEY HAVE GAINED. INTERNATIONAL INNOVATION GRANT - $100,000 PROVIDED FIVE (5) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT CAN HAVE A SIGNIFICANT IMPACT ON CANCER CONTROL IN LOW- AND MIDDLE-INCOME COUNTRIES. THE INTERNATIONAL INNOVATION GRANT PROGRAM IS INTENDED TO SUPPORT PROPOSALS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS. GIANNI BONADONNA BREAST CANCER RESEARCH FELLOWSHIP - $50,000 PROVIDED ONE (1) ONE-YEAR FELLOWSHIP THAT ENABLES AN EARLY-CAREER INVESTIGATOR TO UNDERTAKE A BREAST CANCER PROJECT UNDER THE MENTORSHIP OF THE GIANNI BONADONNA BREAST CANCER AWARD RECIPIENT. THE JAMES B. NACHMAN JUNIOR FACULTY AWARD IN PEDIATRIC ONCOLOGY WAS ESTABLISHED IN MEMORY OF JAMES B. NACHMAN, MD, AN INTERNATIONALLY RENOWNED PEDIATRIC CANCER EXPERT AND PEDIATRICS PROFESSOR. $3,000 PROVIDED FOR ONE JUNIOR FACULTY MEMBER WITH THE HIGHEST SCORING ABSTRACT IN PEDIATRIC ONCOLOGY. 312414 51332 0 QUALITY AND ACCESS TO CARE - REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED. THE QUALITY AND EQUITABLE ACCESS TO CARE PROGRAMS AND INITIATIVES SUPPORTED BY CONQUER CANCER IN 2020 INCLUDE THE FOLLOWING: COVID-19 IMPACTS CANCER FUND - THE COVID-19 IMPACT ON CANCER CARE WAS IMMEDIATE. NEARLY $8,000,000 HELPED RESPOND TO THE SPECIALIZED NEEDS OF THE ONCOLOGY COMMUNITY DURING THIS PUBLIC HEALTH EMERGENCY. THE FOLLOWING PROGRAMS WERE DEVELOPED IN RESPONSE TO THE PANDEMIC: - ASCO SURVEY ON COVID-19 IN ONCOLOGY REGISTRY (ASCO REGISTRY) TO HELP THE ONCOLOGY COMMUNITY LEARN ABOUT THE PATTERN OF SYMPTOMS AND SEVERITY OF COVID-19 AMONG PATIENTS WITH CANCER AND HOW INFECTIONS IMPACT THE DELIVERY OF CANCER CARE AND PATIENT OUTCOMES. - EDUCATION FOR CANCER CARE PROVIDERS - TO SUPPORT CLINICIANS, THE CANCER CARE DELIVERY TEAM, AND PATIENTS WITH CANCER. - EDUCATIONAL RESOURCES FOR PATIENTS WITH CANCER AND CANCER SURVIVORS - REGULARLY UPDATED INFORMATION IN ENGLISH AND SPANISH ABOUT COVID-19 FOR PEOPLE WITH CANCER AND CANCER SURVIVORS THROUGH ASCO'S PATIENT INFORMATION WEBSITE. EQUITY, DIVERSITY AND INCLUSION - THE CONQUER CANCER GRANTS AND AWARDS PROGRAM PROVIDES FUNDING FOR DIFFERENT TYPES OF AWARD OPPORTUNTIES FOR ONCOLOGY FELLOWS, CLINICAL PRACTICES, AND INTERNATIONAL RESEARCHERS AND PROGRAMS FOR MEDICAL STUDENTS AND RESIDENTS WHO SELF-IDENTITY AS BEING MEMBERS OF UNDERREPRESENTED POPULATIONS. TWO AWARD OPPORTUNITIES ARE AVAILABLE: THE MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR) AND THE RESIDENT TRAVEL AWARD FOR UNDERREPRESENTED POPULATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER AND ALLOWS THEM TO GAIN KNOWLEDGE AND EXPERIENCE IN THE AREAS OF CLINICAL CANCER CARE AND RESEARCH. A MENTORING COMPONENT IS INCLUDED IN THE MSR WHEREBY AWARD RECIPIENTS ARE PAIRED WITH A CLINICAL ONCOLOGIST WHO PROVIDES ACADEMIC AND CAREER GUIDANCE, BOTH DURING AND FOLLOWING THE ROTATION EXPERIENCE. QUALITY TRAINING PROGRAM - AS THE LEADING ONCOLOGY QUALITY IMPROVEMENT (QI) COURSE, ASCO'S QUALITY TRAINING PROGRAM EMPOWERS PRACTICE TEAMS TO IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE BY TEACHING TEAMS HOW TO BALANCE QUALITY IMPROVEMENT PROJECTS WITH DEMANDING SCHEDULES AND COMPETING PRIORITIES. CONTENT HAS BEEN DEVELOPED SPECIFICALLY FOR ONCOLOGY PRACTICE TEAMS AND INCLUDES ACCESS TO RENOWNED FACULTY AND COACHES DURING FIVE FOCUSED DAYS OF LEARNING. DURING THOSE FIVE DAYS, PRACTICE TEAMS ATTEND THREE SESSIONS, WHICH INCLUDE SEMINARS, CASE EXAMPLES, AND SMALL GROUP EXERCISES. LEARNING CONTINUES THROUGHOUT THE SIX-MONTH COURSE, INCLUDING REMOTE COACHING SESSIONS AS NEEDED. EACH TEAM WILL TAKE ITS QUALITY IMPROVEMENT KNOWLEDGE AND SKILLS TO ANOTHER LEVEL, ACCELERATING CHANGE AND IMPROVEMENT. TEAMS WILL WORK ON A PROBLEM OF THEIR OWN CHOOSING, WHICH COULD RANGE FROM IMPROVING CARE COORDINATION OR PATIENT SAFETY TO A SPECIFIC ORAL CHEMOTHERAPY PROJECT. 51332 42667 PATIENT EDUCATION & INFORMATION 51332 42667 18763796 true true false false false false false false false true false false false false true true true true false false true true true true true false false true true true false false false false false false false false true false false false false true false false false true 1117 0 true 0 true true true false false false false true true false false false false false false X 18 17 false false true false false true true true true false false true true true true true true false false false AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X LINDA JENSEN CFO 5714831320 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 Clifford Hudis MD FACP FASCO Chief Executive Officer 7.0 30.5 X X 0 950644 21375 LINDA JENSEN CPA CFO & EXECUTIVE VICE PRESIDENT 1.0 36.5 X 0 432564 38827 Nancy Daly MS MPH CEO & EXECUTIVE VICE PRESIDENT 36.5 1.0 X 0 412571 41796 Thomas Roberts Jr MD FASCO Chair 1.0 0.0 X X 0 0 0 Sandra Swain MD FACP FASCO Secretary 1.0 0.0 X X 0 0 0 Alexander Casdin Treasurer 1.0 0.0 X X 0 0 0 Howard Burris III MD FACP FASCO Board Member 1.0 2.0 X 0 0 0 Richard Boxer MD FACS Board Member 1.0 0.0 X 0 0 0 Riccardo Braglia Board Member 1.0 0.0 X 0 0 0 Susan Cohn MD FASCO Board Member 1.0 0.0 X 0 0 0 Lawrence Einhorn MD FASCO Board Member 1.0 0.0 X 0 0 0 Raj Mantena RPh Board Member 1.0 0.0 X 0 0 0 Thomas Marsland MD FASCO Board Member 1.0 0.0 X 0 0 0 Robert Mayer MD FASCO Board Member 1.0 0.0 X 0 0 0 Gerald McDougall Board Member 1.0 0.0 X 0 0 0 Anne Moore MD FASCO Board Member 1.0 0.0 X 0 0 0 W Charles Penley MD FASCO Board Member 1.0 0.0 X 0 0 0 Amy Peterson MD Board Member 1.0 0.0 X 0 0 0 Steven Rosen MD FACP FASCO Board Member 1.0 0.0 X 0 0 0 Margaret Tempero MD FASCO Board Member 1.0 0.0 X 0 0 0 CRAIG NICHOLS MD FACP FASCO BOARD MEMBER 1.0 0.0 X 0 0 0 0 1795779 101998 0 false true false TRUE NORTH INC 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 FUND. STRAT. & MKTG 922560 Faircom NY 12 WEST 27TH STREET 13TH FLOOR NEW YORK NY 10001 DIRECT MAIL SOLICIT. 854221 2 9789 948550 1242665 7205000 25389079 301302 34795083 ADVERTISING 900009 472500 472500 GRANTS EXPERTISE 900009 150000 150000 622500 1592952 1592952 0 0 0 0 0 53994847 57950853 -3956006 -3956006 -3956006 0 1242665 11891 -11891 -11891 0 0 0 0 0 0 0 33042638 150000 472500 -2374945 13537700 13537700 209000 209000 994000 994000 0 0 0 0 0 0 0 6873758 2996465 486837 3390456 0 21195 21195 0 222000 222000 31102 31102 441314 258906 11966 170442 164101 164101 886300 144170 28710 713420 929700 166526 18266 744908 0 725033 338745 111865 274423 96171 61381 12331 22459 0 110234 56903 12530 40801 0 0 0 0 25241608 18763796 734802 5743010 5649132 12722183 0 0 6312068 5286368 610 0 0 0 0 0 0 0 0 0 297353 246172 0 0 76413045 89668691 0 0 0 0 0 0 994172 0 89666380 107923414 299017 173364 3072066 5890831 3825438 2173918 0 0 0 0 0 0 0 0 0 0 0 1011216 7196521 9249329 X 40974084 42169176 41495775 56504909 82469859 98674085 89666380 107923414 7801030 8403196 X false true X true false X 23158842 29032906 31998377 27209762 34945083 146344970 0 0 23158842 29032906 31998377 27209762 34945083 146344970 42710993 103633977 877067 908055 719934 2667684 1592952 6765692 269300 276883 546183 0 153656845 0.67445 0.68896 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 27740161 6504115 2786765 1338480 35692561 17571755 8235901 2772005 839500 27740161 17114411 2133374 -964377 711653 17571755 10363214 6170675 1125396 544874 17114411 9169527 1364000 280187 450500 10363214 1.00000 false false 0 DUE TO ASCO 1011216 1011216 X 41426623 8403196 8403196 33023427 31102 -11891 19211 33042638 25222397 25222397 31102 -11891 19211 25241608 PART V, LINE 4: PERMANENTLY RESTRICTED NET ASSETS OF DONOR-RESTRICTED ENDOWMENT FUNDS ARE PRESERVED, ABSENT EXPLICIT DIRECTION FROM THE DONOR. INTEREST FROM THE PERMANENTLY RESTRICTED FUNDS IS INTENDED TO FUND FUTURE RESEARCH AND/OR EDUCATIONAL AWARDS. PART V, LINE 1A-1G: ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. PART X, LINE 2: IN ACCORDANCE WITH GAAP, THE FOUNDATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED AN EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE CONQUER CANCER FOUNDATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, THE FOUNDATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE DECEMBER 31, 2017 PART XI, LINE 4B FUNDRAISING EXPENSES $(11,891) PART XII, LINE 4B FUNDRAISING EXPENSES $(11,891) true Europe (Including Iceland and Greenland) 0 0 Program Services AWARDS & GRANTS 73000 Central America and the Caribbean 0 0 Program Services AWARDS & GRANTS 90000 North America 0 0 Program Services AWARDS & GRANTS 766000 Sub-Saharan Africa 0 0 Program Services AWARDS & GRANTS 60000 East Asia and the Pacific 0 0 Program Services AWARDS & GRANTS 5000 0 0 0 0 994000 994000 Central America and the Caribbean Int'l Innovation Grant 20000 WIRE North America Advanced Clinical Research Award in Breast Cancer 450000 WIRE North America Young Investigator Award 50000 WIRE North America Young Investigator Award 50000 WIRE North America Young Investigator Award 50000 WIRE North America Young Investigator Award 50000 WIRE North America Global Oncology Young Investigator Award 50000 WIRE North America Long-term International Fellowship 50000 WIRE Sub-Saharan Africa Int'l Innovation Grant 20000 WIRE Europe Young Investigator Award 50000 WIRE Central America and the Caribbean Int'l Innovation Grant 20000 WIRE Central America and the Caribbean Global Oncology Young Investigator Award 50000 WIRE Sub-Saharan Africa Int'l Innovation Grant 20000 WIRE Sub-Saharan Africa Int'l Innovation Grant 20000 WIRE 14 Merit Award Europe 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award Europe 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award North America 1 1000 WIRE Merit Award East Asia and the Pacific 1 1000 WIRE false false false false false false PART I, LINE 2: EXPLANATION: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. X X X X X X true TRUE NORTH 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 PAID ONLINE ADVERTISING false 365932 168000 197932 FAIRCOM NEW YORK 12 WEST 27TH STREET 13TH FLOOR NEW YORK NY 10001 DIRECT MAIL SOLICIT. false 374544 54000 320544 740476 222000 518476 AL CA CO CT DC FL GA KS KY ME MD MA MI MS NV NH NJ NY NC ND OK OR PA RI SC TN UT WA WI An Evening CC 1028825 1028825 11891 WWC OCT SALON 68340 68340 4 145000 145000 1242165 1242165 11891 11891 -11891 FORM 990, SCHEDULE G, PART I, LINE 1: THE RETAINER FEES ARE PAID FOR THE WORK THAT FAIRCOM NY DOES ON MANAGING OUR ACCOUNT. THIS INCLUDES STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. THE OTHER FEES ARE FOR THE PRODUCTION OF THE ACTUAL MAILINGS THEMSELVES, POSTAGE, PRINTING, ACTUAL LIST RENTALS, ETC. TRUE NORTH PROVIDED DONOR STRATEGY CONSULTATION. true Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 100656007 131624182 501(C)(3) 1250000 CDA, YIA Dana-Farber Cancer Institute 44 Binney Street Boston MA 02115 042263040 501(C)(3) 1100000 CDA, YIA The Univ of Tx MD Anderson Cancer Center 1515 Holcombe Boulevard Houston TX 77030 746001118 501(C)(3) 650000 CDA, YIA City of Hope 1500 East Duarte Road Duarte CA 910103000 953432210 501(C)(3) 550000 Research Prof, YIA Massachusetts General Hospital 55 Fruit Street Boston MA 021142696 042697983 501(C)(3) 400000 CDA Yale University 333 Cedar Street New Haven CT 065208028 060646973 501(C)(3) 250000 CDA, YIA University of Pennsylvania 3400 SPRUCE ST 16TH FLOOR Philadelphia PA 19104 231352685 501(C)(3) 250000 CDA, YIA St Jude Children's Research Hospital 262 Danny Thomas Pl Memphis TN 381053678 620646012 501(C)(3) 250000 CDA, YIA Johns Hopkins University 401 North Broadway Baltimore MD 21231 520595110 501(C)(3) 200000 YIA University of California Davis 1850 Research Park Dr Davis CA 95618 946036494 501(C)(3) 200000 CDA Mayo Clinic Minnesota 200 First Street SW Rochester MN 55905 416011702 501(C)(3) 200000 YIA University of Washington 4333 Brooklyn Ave NE Seattle WA 981959472 916001537 501(C)(3) 200000 CDA University of California San Francisco 2340 Sutter St San Francisco CA 941150128 946036493 501(C)(3) 200000 YIA Stanford University 800 Welch Road Stanford CA 943055796 941156365 501(C)(3) 167000 YIA, MSR Columbia University Medical Center 630 West 168th Street New York NY 10032 135598093 501(C)(3) 150000 YIA The University of NC at Chapel Hill 102 Mason Farm Rd Chapel Hill NC 275997295 566001393 501(C)(3) 150000 YIA Fred Hutchinson Cancer Research Center 1100 Fairview Avenue N Seattle WA 98109 237156071 501(C)(3) 150000 YIA The Ohio State University 300 W 10th Avenue Columbus OH 43210 316025986 501(C)(3) 100000 YIA Weill Medical College of Cornell University 525 E 68th Street New York NY 10065 131623978 501(C)(3) 100000 YIA Mayo Clinic Florida 4500 San Pablo Road Jacksonville FL 32224 590714831 501(C)(3) 51500 YIA; MSR University of Wisconsin 600 Highland Avenue Madison WI 537920001 396006492 501(C)(3) 50000 YIA Seattle Children's Hospital 1100 Olive Way Seattle WA 98101 910564748 501(C)(3) 50000 YIA Michigan State University 426 Auditorium Rd East Lansing MI 488242600 386005984 501(C)(3) 50000 YIA Montefiore Medical Center 111 East 210th Street Bronx NY 10467 131740114 501(C)(3) 50000 YIA University of Florida Board of Trustees 207 Grinter Hall Gainesville FL 32611 596002052 501(C)(3) 50000 YIA Emory University 201 Dowman Drive Atlanta GA 30322 580566256 501(C)(3) 50000 YIA University of Rochester Wilmot Cancer Ctr 518 Hylan Building Rochester NY 14627 160743209 501(C)(3) 50000 YIA University of Alabama at Birmingham 1802 Sixth Ave S Birmingham AL 352943300 636005396 501(C)(3) 50000 YIA Brigham and Women's Hospital 75 Francis Street Boston MA 02115 042312909 501(C)(3) 50000 YIA Icahn School of Medicine at Mount Sinai 5 E 98th Street New York NY 100296105 136171197 501(C)(3) 50000 YIA Northwestern University 303 E Superior Street Chicago IL 60611 362167817 501(C)(3) 50000 YIA George Washington University 2121 I St NW Washington DC 20052 530196584 501(C)(3) 8500 MSR Campbell School of Osteopathic Medicine 4350 US-421 Lillington NC 27546 560529940 501(C)(3) 8500 MSR David Geffen School of Medicine at UCLA 10833 Le Conte Avenue Los Angeles CA 90095 956006143 501(C)(3) 8500 MSR CUNY School of Medicine 160 Convent Avenue New York NY 10031 136000565 501(C)(3) 8500 MSR Wright State University Boonshoft School 3640 Colonel Glenn Highway Fairborn OH 45324 310732831 501(C)(3) 8500 MSR Medical College of Wisconsin 8701 W Watertown Plank Wauwatosa WI 53226 390806261 501(C)(3) 8500 MSR Howard University 2400 6th Street NW Washington DC 20059 530204707 501(C)(3) 8500 MSR University of South Alabama College of Med 307 N University Boulevard Mobile AL 36688 630477348 501(C)(3) 8500 MSR 39 MERIT AWARDS 105 105000 MEDICAL STUDENT ROTATION AWARD 11 93500 RESIDENT TRAVEL AWARDS 7 10500 PART I, LINE 1: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CCF AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CCF'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. part II, award abbreviations: YIA: YOUNG INVESTIGATOR AWARD CDA: CAREER DEVELOPMENT AWARD MSR: MEDICAL STUDENT ROTATION ACRA: ADVANCED CLINICAL RESEARCH AWARD false false false false false false false false false Clifford Hudis MD FACP FASCO Chief Executive Officer 0 876885 0 73759 0 0 0 21375 0 0 0 972019 0 0 Nancy Daly MS MPH CEO & EXECUTIVE VICE PRESIDENT 0 402571 0 10000 0 0 0 21375 0 20421 0 454367 0 0 LINDA JENSEN CPA CFO & EXECUTIVE VICE PRESIDENT 0 422564 0 10000 0 0 0 21375 0 17452 0 471391 0 0 PART I, LINE 3: EXPLANATION: COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 17 301302 FMV false true false FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES: PATIENT EDUCATION AND INFORMATION - WELL-INFORMED, EDUCATED PATIENTS ARE THEIR OWN BEST ADVOCATES, AS WELL AS INVALUABLE PARTNERS FOR DOCTORS. CONQUER CANCER SUPPORTS PROGRAMS AND ACCURATE, DOCTOR-APPROVED CANCER INFORMATION AND RESOURCES BOTH IN PRINT AND ONLINE, THAT EDUCATE PATIENTS AND THE PUBLIC ABOUT CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. FUNDING IN THIS AREA ALLOWS CONQUER CANCER TO CONTINUE AND EXPAND OUR WORK TO INFORM PATIENTS. HIGHLIGHTS OF PATIENT EDUCATION AND INFORMATION PROGRAMS AND ACTIVITIES SUPPORTED BY CONQUER CANCER IN 2020 INCLUDE THE FOLLOWING: CANCER.NET- CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. THE WEBSITE PROVIDES TIMELY, COMPREHENSIVE INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS. ALL CONTENT IS SUBJECT TO A FORMAL PEER-REVIEW PROCESS BY THE CANCER.NET EDITORIAL BOARD, COMPOSED OF MORE THAN 150 MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGISTS, PHYSICIAN ASSISTANTS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENT ADVOCATES AND INCLUDES PEER-REVIEWED INFORMATION ON MORE THAN 120 TYPES OF CANCER AND SYNDROMES, INCLUDING RISK FACTORS, DIAGNOSIS, FINDING AN ONCOLOGIST, TREATMENT, MANAGING SIDE EFFECTS, CLINICAL TRIALS, AND AFTER TREATMENT, CAREGIVING, COPING STRATEGIES, AND SURVIVORSHIP. INFORMATION IS DELIVERED IN WRITTEN ARTICLES, VIDEOS, AND AUDIO PODCASTS. THIS INFORMATION IS MADE AVAILABLE FREE TO THE PUBLIC. FORM 990, PART VI, SECTION A, LINE 1: AS OF DECEMBER 31, 2020, THE BOARD OF DIRECTORS OF CONQUER CANCER INCLUDED EIGHTEEN (18) DIRECTORS WITH VOTING RIGHTS, AND ONE (1) WITHOUT VOTING RIGHTS. ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS HAVE THE SAME VOTING RIGHTS. DURING THE REPORTED TAX YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS CONSISTENT WITH CONQUER CANCER'S BYLAWS. THE EXECUTIVE COMMITTEE IS COMPOSED OF SIX MEMBERS, WHO ARE THE CHAIR OF THE BOARD OF DIRECTORS, THE SECRETARY, THE TREASURER, THE EXECUTIVE VICE chair AND CHIEF EXECUTIVE OFFICER (NONVOTING), AND A SIXTH DIRECTOR WHO IS NOMINATED BY THE CHAIR OF THE BOARD AND ELECTED BY A MAJORITY OF THE VOTING MEMBERS OF THE BOARD OF DIRECTORS. ALL OF THE MEMBERS OF THE EXECUTIVE COMMITTEE EXCEPT THE CHIEF EXECUTIVE OFFICER ARE ENTITLED TO VOTE. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY CONQUER CANCER'S BYLAWS, WHICH PROVIDE THAT EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW AND EXCEPT AS SPECIFIED IN THE BYLAWS, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD MEETING. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH CONQUER CANCER'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 2: DR. CLIFFORD HUDIS, NANCY DALY, AND LINDA JENSEN WERE ALL EMPLOYED BY ASCO. DR. CLIFFORD HUDIS SERVED AS CHIEF EXECUTIVE OFFICER OF ASCO, AND LINDA JENSEN SERVED AS CHIEF FINANCIAL OFFICER OF ASCO. FORM 990, PART VI, SECTION A, LINE 4: CONQUER CANCER'S BYLAWS AND ARTICLES OF INCORPORATION WERE AMENDED TO ADD THE POSITION OF EXECUTIVE VICE CHAIR, WHICH IS A VOTING MEMBER OF THE BOARD OF DIRECTORS AND EXECUTIVE COMMITTEE. FORM 990, PART VI, SECTION A, LINE 7A: CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B: THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B: AN ELECTRONIC COPY OF THE CONQUER CANCER FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS BEFORE IT WAS FILED. THE CONQUER CANCER FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CEO AND THE GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C: CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINES 15A & 15B: THE CEO OF CONQUER CANCER, THE EXECUTIVE VICE CHAIR OF CONQUER CANCER, AND THE CFO OF CONQUER CANCER SERVE AS EMPLOYEES OF ASCO. INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19: CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD 800 ALEXANDRIA VA 22314 136180380 education NY 501(C)(3) 10 NA false ASCO ASSOCIATION 2318 MILL ROAD ALEXANDRIA VA 22314 833561693 MEMBER SERV. VA 501(C)(6) ASCO false ASCO ASSOCIATION PAC 2318 MILL ROAD ALEXANDRIA VA 22314 844213157 PAC VA 527 ASCO ASSOC false false true true true false false false false false false true true true true true true true false false